Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -38.98% is 410% below its 5-year average of -7.65%, around the middle of its 5-year range (-70.93%–16.78%).
20.57% below its 12-month average of -32.33%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25.26%.
NET PROFIT MARGIN
-38.98%
NET PROFIT MARGIN AVG TTM
-32.33%
NET PROFIT MARGIN AVG 3Y
-15.03%
NET PROFIT MARGIN AVG 5Y
-7.65%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-20.57%
CURRENT VS 3Y AVG
-159.30%
CURRENT VS 5Y AVG
-409.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 644 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$726.43M
Net Profit Margin
-38.98%
TTM Avg
-32.33%
3Y Avg
-15.03%
5Y Avg
-7.65%
Market Cap
$725.93M
Net Profit Margin
-170055.93%
TTM Avg
-70304.07%
3Y Avg
-35619.60%
5Y Avg
-24164.90%
Market Cap
$734.01M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$713.54M
Net Profit Margin
5.93%
TTM Avg
9.51%
3Y Avg
5.53%
5Y Avg
9.43%
Market Cap
$713.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$709.67M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$696.18M
Net Profit Margin
-4619.67%
TTM Avg
-3871.87%
3Y Avg
-2595.36%
5Y Avg
-1815.29%
Market Cap
$757.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3758.80%
5Y Avg
-9679.73%
Market Cap
$759.69M
Net Profit Margin
-4490.89%
TTM Avg
-2245.45%
3Y Avg
-2245.45%
5Y Avg
-2245.45%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $726.43M | -38.98% | -32.33% | -15.03% | -7.65% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $725.93M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $734.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $713.54M | 5.93% | 9.51% | 5.53% | 9.43% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $709.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anteris Technologies Global Corp. (AVR)vs › | $696.18M | -4619.67% | -3871.87% | -2595.36% | -1815.29% |
| Candel Therapeutics, Inc. (CADL)vs › | $757.61M | 0.00% | 0.00% | -3758.80% | -9679.73% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $759.69M | -4490.89% | -2245.45% | -2245.45% | -2245.45% |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.56M | 1.92% | 0.94% | -28.83% | -18.64% |
Operating Margin
-21.6%
Net Profit Margin
-39.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -25.26% |
| 2026-03-31 | -42.75% |
| 2025-12-31 | -70.93% |
| 2025-09-30 | -10.48% |
| 2025-06-30 | -12.24% |
| 2025-03-31 | -27.50% |
| 2024-12-31 | 16.78% |
| 2024-09-30 | 1.83% |
| 2024-06-30 | -22.38% |
| 2024-03-31 | -13.75% |
| 2023-12-31 | 9.45% |
| 2023-09-30 | -13.45% |
| 2023-06-30 | -8.83% |
| 2023-03-31 | -18.35% |
| 2022-12-31 | 7.30% |
| 2022-09-30 | 4.12% |
| 2022-06-30 | -1.49% |
| 2022-03-31 | -5.76% |
| 2021-12-31 | -3.06% |
| 2021-09-30 | 4.13% |
| 2021-06-30 | 8.78% |
| 2021-03-31 | 0.42% |
| 2020-12-31 | 18.29% |
| 2020-09-30 | 26.06% |
| 2020-06-30 | 42.39% |
| 2020-03-31 | -4.66% |
